Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
- Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants
- Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved
LONDON & NEW YORK–(BUSINESS WIRE)–Sep. 10, 2026– Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved.
The recipients were selected through a competitive application process based on their expertise and proven ability to develop and deliver high-quality training at scale. They will remain independent training and education providers, retaining ownership and control of their training programs, content, faculty selection, and educational design, consistent with ACCME Standards for Integrity and Independence in Accredited Continuing planned Education, with Compass providing the grant program funding and recognizing them as grant awardees. In all, five organizations were awarded the grant, expanded from the originally three recipients due to the overall quality of applicants:
- CME Outfitters, LLC (Radnor, PA)
- Emory University (Atlanta, GA)
- Fluence International, Inc. (Bronx, NY)
- Integrative Psychiatry Institute, LLC (Longmont, CO)
- Strata Mental Health Solutions, LLC (Atlanta, GA)
“As the leader in psychedelic treatment, we believe advancing COMP360 to reach patients requires doing it the right way – with scientific rigor, detailed intention and an unwavering focus on patient safety, access and experience,” said Dr. Steve Levine, Chief Patient Officer at Compass Pathways. “COMP360 represents a distinctly new approach to treatment-resistant depression management, and we recognize that delivering this model of care requires a care workforce with the right skills and capabilities to offer a high-quality experience from preparation, treatment administration, and through follow-up. We are thrilled to work with the organizations selected through a competitive review process, and confident in their ability to help drive system readiness for what we believe to be the future of mental health care.”
Compass has also created guidance documents for real-world delivery and consistent training guidance available upon request. These documents, developed independently by Compass, are separate from the training programs developed by grant awardees, and may serve as resources for others to develop trainings. Interested HCPs may submit requests to: USMedInfo@compasspathways.com.
More
